Button Capital - Investor Profile and Portfolio

Developer of compounds to protect against tissue degradation and promote healing during illness or injury. The pipeline candidates include SB-061 for osteoarthritis, and SB-0303 for peripheral vascular disease/vein graft failure, fibrosis, and cancer.

Developer of immunotherapy platform for infectious disease prevention and cancer therapy. It offers T-cell therapy platform for development of therapeutics which include FLOVID-20 for covid, FlowVAx is an Ebola vaccine, FlowVax BreastCA for breast cancers, and FlowVax HPV for HPV-induced cervical and throat cancer.

Sinorda is developing personalized anticancer vaccines & diagnostics. The lead candidate of the company, SentoClone, a sentinel lymph node T cells immune therapy is in phase II in the EU targeted for metastasis and recurrence of colorectal cancer. Other candidates, CD8+cytotoxic T cells (Cytox-sinorda) & Dendritic cells (DCs) vaccines. Also developing tumor diagnostic, based on sentinel lymph node technology & flow cytometry, is flexible for detecting metastasis of cancer. The company has two branches, Jiangsu Sinorda Biomedicine, China and SentoClone, Sweden. Also, has an EU-certified GMP cell engineering facility.

Advanced stereotactic radiotherapy solutions improving breast cancer care and patient lives. The company is a medical technology innovator focused on developing advanced stereotactic radiotherapy solutions. Their core offering, GammaPod, is specifically designed for early-stage breast cancer treatment. They aim to improve the quality of cancer care and the lives of patients through non-invasive, non-surgical treatment options with faster recovery times. The company builds technology with a singular focus: breast cancer, offering patient-friendly, protective, and proven solutions. They are committed to innovation in the radiotherapy industry, with a focus on regulatory compliance and quality assurance.